OCN action - Oncology Certified Nurse - 2023 Updated: 2024 | ||||||||
Real OCN questions that showed up in test today | ||||||||
|
||||||||
Exam Code: OCN Oncology Certified Nurse - 2023 action January 2024 by Killexams.com team | ||||||||
OCN Oncology Certified Nurse - 2023 Exam ID : OCN Exam Title : Oncology Certified Nurse (OCN®) Questions : 165 Duration : 3 hours Exam Type : multiple-choice Test Content Outline (Effective 2020) I. Care Continuum - 19% A. Health promotion and disease prevention (e.g., high-risk behaviors; preventive health practices) B. Screening and early detection C. Navigation D. Advance care planning (e.g., advance directives) E. Epidemiology 1. Modifiable risk factors (e.g., smoking, diet, exercise, occupation) 2. Non-modifiable risk factors (e.g., age, gender, genetics) F. Survivorship 1. Rehabilitation 2. Recurrence concerns 3. Financial concerns 4. Employment concerns 5. Insurance concerns 6. Family and social support concerns 7. Sexuality concerns G. Treatment-related considerations 1. Delayed-onset side effects 2. Chronic side effects 3. Secondary malignancies 4. Follow-up care H. End-of-life care 1. Grief 2. Bereavement 3. Hospice care 4. Caregiver support 5. Interdisciplinary team 6. Pharmacologic comfort measures 7. Non-pharmacologic comfort measures II. Oncology Nursing Practice - 17 % A. Scientific basis 1. Carcinogenesis 2. Immunology 3. Clinical trials (e.g., research protocols) B. Site-specific cancer considerations 1. Pathophysiology 2. Common metastatic locations 3. Diagnostic measures 4. Prognosis 5. Classification 6. Staging 7. Histological grading C. Scope, standards, and related issues 1. Standards of care (nursing process) 2. Legal (including documentation) 3. Accreditation (e.g., The Joint Commission) 4. Self-care (e.g., managing compassion fatigue) D. Standards of professional performance 1. Ethics (e.g., patient advocacy) 2. Education 3. Evidence-based practice (e.g., Putting Evidence Into Practice (PEP) guidelines) and research 4. Quality of practice 5. Communication 6. Leadership 7. Collaboration 8. Professional practice evaluation 9. Resource utilization 10. Environmental health (e.g., safety, personal protective equipment, safe handling) III. Treatment Modalities - 19% A. Surgery B. Blood and marrow transplant C. Radiation therapy D. Chemotherapy E. Biotherapy F. Immunotherapy G. Vascular Access Devices (VADs) for treatment administration H. Targeted Therapy IV. Symptom Management and Palliative Care - 23% A. Etiology and patterns of symptoms (acute, chronic, late) B. Anatomical and surgical alterations (e.g., lymphedema, ostomy, site-specific radiation) C. Pharmacologic interventions D. Complementary and integrative modalities (e.g., massage, acupuncture, herbal supplements) E. Palliative care considerations F. Alterations in functioning 1. Hematologic 2. Immune system 3. Gastrointestinal 4. Genitourinary 5. Integumentary 6. Respiratory 7. Cardiovascular 8. Neurological 9. Musculoskeletal 10. Nutrition 11. Cognition 12. Energy level (i.e., fatigue) V. Oncologic Emergencies - 12% A. Disseminated intravascular coagulation (DIC) B. Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) C. Sepsis (including septic shock) D. Tumor lysis syndrome E. Hypersensitivity F. Anaphylaxis G. Hypercalcemia H. Cardiac tamponade I. Spinal cord compression J. Superior vena cava syndrome K. Increased intracranial pressure L. Obstructions (bowel and urinary) M. Pneumonitis N. Extravasations VI. Psychosocial Dimensions of Care - 10% A. Cultural, spiritual, and religious diversity B. Financial concerns (including available resources) C. Altered body image D. Learning styles and barriers to learning E. Social relationships and family dynamics F. Coping mechanisms and skills G. Support 1. Patient (i.e., individual and group) 2. Caregiver (including family) H. Psychosocial considerations 1. Anxiety 2. Loss and grief 3. Depression 4. Loss of personal control I. Sexuality 1. Reproductive issues (e.g., contraception, fertility) 2. Sexual dysfunction (e.g., physical and psychological effects) 3. Intimacy | ||||||||
Oncology Certified Nurse - 2023 Medical Certified action | ||||||||
Other Medical examsCRRN Certified Rehabilitation Registered NurseCCRN Critical Care Register Nurse CEN Certified Emergency Nurse CFRN Certified Flight Registered Nurse CGFNS Commission on Graduates of Foreign Nursing Schools CNA Certified Nurse Assistant CNN Certified Nephrology Nurse CNOR Certified Nurse Operating Room DANB Dental Assisting National Board Dietitian Dietitian EMT Emergency Medical Technician EPPP Examination for Professional Practice of Psychology FPGEE Foreign Pharmacy Graduate Equivalency NBCOT National Board for Certification of Occupational Therapists - 2023 NCBTMB National Certification Board for Therapeutic Massage & Bodywork NET Nurse Entrance Test NPTE National Physical Therapy Examination OCN Oncology Certified Nurse - 2023 PANCE Physician Assistant National Certifying VTNE Veterinary Technician National Examination (VTNE) CNS Clinical Nurse Specialist NBRC The National Board for Respiratory Care AHM-540 AHM Medical Management AACN-CMC Cardiac Medicine Subspecialty Certification AAMA-CMA AAMA Certified Medical Assistant ABEM-EMC ABEM Emergency Medicine Certificate ACNP AG - Acute Care Nurse Practitioner AEMT NREMT Advanced Emergency Medical Technician AHIMA-CCS Certified Coding Specialist (CPC) (ICD-10-CM) ANCC-CVNC ANCC (RN-BC) Cardiac-Vascular Nursing ANCC-MSN ANCC (RN-BC) Medical-Surgical Nursing ANP-BC ANCC Adult Nurse Practitioner APMLE Podiatry and Medical BCNS-CNS Board Certified Nutrition Specialis BMAT Biomedical Admissions Test CCN CNCB Certified Clinical Nutritionist CCP Certificate in Child Psychology CDCA-ADEX Dental Hygiene CDM Certified Dietary Manager CGRN ABCGN Certified Gastroenterology Registered Nurse CNSC NBNSC Certified Nutrition Support Clinician COMLEX-USA Osteopathic Physician CPM Certified Professional Midwife CRNE Canadian Registered Nurse Examination CVPM Certificate of Veterinary Practice Management DAT Dental Admission Test DHORT Discover Health Occupations Readiness Test DTR Dietetic Technician Registered FNS Fitness Nutrition Specialist MHAP MHA Phlebotomist MSNCB MSNCB Medical-Surgical Nursing Certification NAPLEX North American Pharmacist Licensure Examination NCCT-TSC NCCT Technician in Surgery NCMA-CMA Certified Medical Assistant NCPT National Certified Phlebotomy Technician (NCPT) NE-BC ANCC Nurse Executive Certification NNAAP-NA NNAAP Nurse Aide NREMT-NRP NREMT National Registered Paramedic NREMT-PTE NREMT Paramedic Trauma Exam OCS Ophthalmic Coding Specialist PANRE Physician Assistant National Recertifying Exam PCCN AACN Progressive Critical Care Nursing RDN Registered Dietitian VACC VACC Vascular Access WHNP Women Health Nurse Practitioner AACD American Academy of Cosmetic Dentistry RPFT Registered Pulmonary Function Technologist ACLS Advanced Cardiac Life Support - 2023 GP-Doctor General Practitioner (GP) Doctor GP-MCQS Prometric MCQS for general practitioner (GP) Doctor INBDE Integrated National Board Dental Examination (Day 1 exam) Podiatry-License-Exam-Part-III Podiatry License test Part III - 2023 | ||||||||
Internet is full of free stuff regarding OCN exam, but you will not find any of them updated, valid and accurate. You need not to waste your money on taking test by memorizing outdated OCN dumps. Just go to killexams.com and obtain latest, valid and updated OCN dumps consisting of braindumps Questions Answers taken from real exams. You can trust their OCN dumps. | ||||||||
OCN Dumps OCN Braindumps OCN Real Questions OCN Practice Test OCN dumps free Medical OCN Oncology Certified Nurse http://killexams.com/pass4sure/exam-detail/OCN Question: 94 A male client is diagnosed as having a bowel tumor and several diagnostic tests are prescribed. The nurse understands which test will confirm the diagnosis of malignancy? A. Magnetic resonance imaging B. Computerized tomography scan C. Abdominal ultrasound D. Biopsy of the tumor Answer: D Explanation: Option D: A biopsy is done to determine whether a tumor is malignant or benign through the examination of the sample of tissue taken into a body part. Options A, B, and C: Magnetic resonance imaging, computed tomography scan, and ultrasound will visualize the presence of a mass but will not confirm a diagnosis of malignancy. Question: 95 Vanessa, a community health nurse conducts a health promotion program regarding testicular cancer to community members. The nurse determines that further information needs to be provided if a community member states that which of the following is a sign of testicular cancer? A. Back pain B. Alopecia C. Heavy sensation in the scrotum D. Painless testicular swelling Answer: B Explanation: Option B: Alopecia is not an assessment finding in testicular cancer. Alopecia may occur, however, as a result of radiation or chemotherapy. Options A, C, and D: Back pain, heavy sensation in the scrotum, and painless testicular swelling are assessment findings in testicular cancer. Back pain may indicate metastasis to the retroperitoneal lymph nodes. Question: 96 The male client is receiving external radiation to the neck for cancer of the larynx. The most likely side effect to be expected is: A. Diarrhea B. Dyspnea C. Constipation D. Sore throat Answer: D Explanation: Option D: In general, only the area in the treatment field is affected by the radiation. Skin reactions, fatigue, nausea, and anorexia may occur with radiation to any site, whereas other side effects occur only when specific areas are involved in treatment. A client receiving radiation to the larynx is most likely to experience a sore throat. Options A and C: May occur with radiation to the gastrointestinal tract. Option B: Dyspnea may occur with lung involvement. Question: 97 Nurse Joy is caring for a client with an internal radiation implant. When caring for the client, the nurse should observe which of the following principles? A. Remove the dosimeter badge when entering the clientĆs room B. Individuals younger than 16 years old may be allowed to go in the room as long as they are 6 feet away from the client C. Limit the time with the client to 1 hour per shift D. Do not allow pregnant women into the clientĆs room Answer: D Explanation: Options B and D: Children younger than 16 years of age and pregnant women are not allowed in the clientĆs room to avoid radiation exposure that may harm the children and the developing baby. Option A: The dosimeter badge must be worn when in the clientĆs room. Option C: The time that the nurse spends in a room of a client with an internal radiation implant is 30 minutes per 8-hour shift. Question: 98 A cervical radiation implant is placed in the client for treatment of cervical cancer. The nurse initiates what most appropriate activity order for this client? A. Out of bed ad lib B. Ambulation to the bathroom only C. Bed rest D. Out of bed in a chair only Answer: C Explanation: Option C: The client with a cervical radiation implant should be maintained on bed rest in the dorsal position to prevent movement of the radiation source. The head of the bed is elevated to a maximum of 10 to 15 degrees for comfort. The nurse avoids turning the client on the side. If turning is absolutely necessary, a pillow is placed between the knees and, with the body in straight alignment, the client is logrolled. Question: 99 The nurse is caring for a female client experiencing neutropenia as a result of chemotherapy and develops a plan of care for the client. The nurse plans to: A. Teach the client and family about the need for hand hygiene B. Insert an indwelling urinary catheter to prevent skin breakdown C. Restrict fluid intake D. Restrict all visitors Answer: A Explanation: Option A: In the neutropenic client, meticulous hand hygiene education is implemented for the client, family, visitors, and staff to avoid transmission-based infection. Option B: Invasive measures such as an indwelling urinary catheter should be avoided to prevent infections. Option C: Fluids should be encouraged. Option D: Not all visitors are restricted, but the client is protected from persons with known infections. Question: 100 The home health care nurse is caring for a male client with cancer and the client is complaining of acute pain. The appropriate nursing assessment of the clientĆs pain would include which of the following? A. The clientĆs pain rating B. The nurseĆs impression of the clientĆs pain C. Nonverbal cues from the client D. Pain relief after appropriate nursing intervention Answer: A Explanation: Option A: The clientĆs self-report is a critical component of pain assessment. The nurse should ask the client about the description of the pain and listen carefully to the clientĆs words used to describe the pain. Option B: Nonverbal cues from the client are important but are not the most appropriate pain assessment measure. Option C: The nurseĆs impression of the clientĆs pain is not appropriate in determining the clientĆs level of pain. Option D: Assessing pain relief is an important measure, but this option is not related to the subject of the question. For More exams visit https://killexams.com/vendors-exam-list | ||||||||
A lawsuit against Saint-Gobain, the French manufacturing company accused of contaminating drinking water in towns in southern New Hampshire with harmful PFAS chemicals, has entered a new phase after a federal judge said part of the case could be managed as a class action. Under the decision, thousands of residents who live or have lived near the Merrimack facility since 2016 could be part of the class action. The class could include almost 9,000 households within Merrimack and 382 homes in Bedford within the Merrimack Village District Water Works service area, and 1,200 homes with private wells in the area. PFAS are a class of man-made chemicals that have been used for decades in a variety of consumer products and have been linked torisks to human health like increased risk for certain kinds of cancers. Elevated levels of those chemicals were discovered around Saint-Gobain’s Merrimack facility in 2016. The company knew about elevated PFAS levels in their emissions since at least 2004. The company has provided bottled water and alternative drinking water to residents affected by contamination through a consent decree with the state of New Hampshire. They announced they were closing their Merrimack facility last year. A class action lawsuit brought by people living near the Saint Gobain manufacturing facility in Merrimack who say they were exposed to PFOA, one of many PFAS chemicals, was filed in 2016. Judge Joseph Laplante’s Dec. 29 decision splits that case into two phases. In the first, the court would determine whether Saint-Gobain’s Merrimack facility was liable for contamination for nearby residents as a whole, instead of for each individual case. The second phase will determine how individuals may be compensated for the contamination on a case-by-case basis. Laplante denied class certification for the claim in the lawsuit that Saint-Gobain caused a “nuisance,” saying that whether Saint-Gobain interfered with each person’s use and enjoyment of their property would need to be determined on an individual basis. But he certified the class for the purpose of the claims that Saint-Gobain trespassed on residents’ land by causing PFAS chemicals to enter without their permission and that the company acted negligently by emitting PFAS, not investigating and mitigating contamination adequately, and not warning residents about the risks of the chemicals. Whether Saint-Gobain is liable for emitting the chemicals, how much they foresaw the consequences, and whether they adequately investigated, mitigated, and warned people about them can be determined for all residents together, the judge said. Mindi Messmer, a former state lawmaker who has called for more accountability for Saint-Gobain over their PFAS emissions, said the decision is a victory for those who may have been affected by the chemicals. “This is a big step in that the court is signaling that there is at least some validity to the claims made by the plaintiffs,” she said. According to court documents, the plaintiffs are seeking compensation for non-economic losses, like the loss of enjoyment of their property, and compensation for economic losses related to the decreased value of their properties and the cost of mitigating contamination. Experts for the plaintiffs found that damages in the area addressed in the lawsuit would be around $578 million for losses in property value and $2.6 million for those who switched from private wells to municipal water. Last March, the New Hampshire Supreme Court decided that people exposed to toxins could not recover the cost of medical testing from polluters if they’re not currently sick in a ruling connected to the case. That came as a disappointment to Laurene Allen, who started Merrimack Citizens for Clean Water to advocate for those affected by PFAS contamination. She said the Supreme Court decision weakened the class action suit. “When you talk to people you hear about a health condition, then another health condition, then another health condition,” she said. “For many people, you’re watching what’s happening around you, and you know why it’s happening, and no one’s doing anything about it, and your health isn’t properly supported in terms of monitoring. That’s why medical monitoring is so important.” But despite the lack of medical monitoring cost recovery, Allen said the certification of the class in the lawsuit was validating. And, she said, she hopes the case goes to trial. Two other class action lawsuits against Saint-Gobain for PFAS pollution – one in Hoosick Falls, N.Y., and one in Bennington, Vt. – ended in settlements in which the company did not admit wrongdoing or liability. “I would love to see this go to trial and that they truly be held accountable for the harm that they caused,” Allen said. “What they have never once been held accountable for is the harm they have caused, the harm to human health and the forever contamination of their environment.” Two law firms in New York announced the filing of a class action lawsuit by investors against Inspire Medical Systems (NYSE:INSP). Bragar Eagel & Squire, P.C., and Bernstein Liebhard LLP filed on behalf of persons or entities who purchased or otherwise acquired Inspire Medical common stock between May 3, 2023, and Nov. 7, 2023. The Minneapolis-based company develops minimally invasive implantable products for treating obstructive sleep apnea. It offers an alternative to the traditional CPAP machines made by the likes of Philips and ResMed. Inspire Medical’s reputation has grown over the past several years as Philips dealt with a massive CPAP recall and people moved away from that method of treatment. Outlining the class action allegations against Inspire MedicalAccording to the law firms, Inspire introduced a pilot program in 2022. In this program, the company’s advisor care program team could directly access doctors’ electronic schedules and schedule appointments online. Throughout the period outlined in the class action, Inspire allegedly touted the program’s effectiveness. The suits say the company boasted a 30% improvement in physician appointments. By August 2023, the suit alleges Inspire claimed more than 60 centers used the tool. The suit alleges that during the May-August period, Inspire misled investors and/or failed to disclose key outcomes. Among the allegations, the firms say that customers encountered challenges with previous authorization submissions and scheduling appointments, despite the acceleration program. The slowdown in authorization submissions from these challenges allegedly led to a shortfall of hundreds of implant procedures. As a result, the law firms say, Inspire’s positive statements about financial guidance, business, operations and prospects “were materially false and misleading and/or lacked a reasonable basis at all relevant times.” Inspire’s third-quarter earnings — announced on Nov. 7 — included revenues that fell shy of expectations on Wall Street. The company also reported a decline in prior authorization submissions for patients seeking Inspire therapy. It also said it started to “track” problems with the acceleration program no later than the second quarter of 2023. In response to the earnings, shares of INSP fell approximately 20% from $161.74 at close on Nov. 7 to $129.95 on Nov. 8. The stock has since rebounded, though, sitting at a share price of $201 before the market opened today, Dec. 27. An Inspire spokesperson shared the following response to a request for comment:
Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Inspire Medical To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Inspire Medical stock or options between May 3, 2023 and November 7, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/INSP. There is no cost or obligation to you. New York, New York--(Newsfile Corp. - December 29, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inspire Medical Systems, Inc. ("Inspire Medical" or the "Company") (NYSE: INSP) and reminds investors of the February 20, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) despite the Acceleration Program, customers were encountering challenges with the prior authorization submission process, including with the scheduling of appointments; (2) a slowdown in prior authorization submissions arising from these challenges led to a shortfall of hundreds of procedures to implant the Company's OSA device; and (3) as a result, Defendants' positive statements about the Company's financial guidance, business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth emerged after the close of markets on November 7, 2023, when the Company announced disappointing earnings results for the third quarter of 2023, including "a decline in prior authorization submissions for patients seeking Inspire therapy." Inspire Medical further admitted it had started to "track" problems with the Acceleration Program no later than the second quarter of 2023, the Company "had strong confirmation" of the problems with the Acceleration Program, and the Company "realized they needed to take some corrective action." In response to this news, shares of Inspire Medical declined approximately 20%, from a closing price of $161.74 per share on November 7, 2023, to a closing price of $129.95 per share on November 8, 2023. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Inspire Medical's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not ensure or predict a similar outcome with respect to any future matter. They welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/192404 Community Action of Etowah County Inc. will begin scheduling appointments for its regular and crisis low-income heating programs on Jan. 17. Office hours are 8 a.m. to 5 p.m. Monday through Friday; the office is closed from noon to 1 p.m. for lunch. Only applicants with pending applications will be served on Fridays. Applicants are eligible if the household heats with natural or butane gas, or is totally electric, and applicants meet Fiscal Year 2024 eligibility requirements. The Regular Heating Program provides general heating assistance to eligible households that meet the guidelines set by the Alabama Department of Economic and Community Affairs. The Crisis Heating Program provides assistance to households with an energy-related crisis. Any household member with a medical situation caused or aggravated by extreme heat or cold may apply for crisis assistance, with verification by a physician or nurse on the agency-provided “Physician/Nurse Medical Statement.” Households must meet all points of eligibility before assistance can be awarded. Documents provided must be for the month before the date of an appointment. The following documents are required and may be submitted through fax or email:
Household members who are unemployed and currently do not have income must complete a "Declaration of Household Income" form provided by Community Action of Etowah County. Employed household members must provide check stubs as verification of income. Bank statements cannot be used to verify income from SS or SSI benefits. If a person in the household has applied for SS or SSI and the status is pending, a letter from the Social Security office or a representation letter from any attorney is required. Custody claims must be Checked with legal documentation, such as guardianship declarations. Residents who live in assisted living or public housing projects, and are responsible for out-of-pocket payments for utility bills, may qualify for the regular and crisis utility assistance program. In addition to all other eligibility requirements, households must provide proof of out-of-pocket "utility allowance" and "utility reimbursement" payments (lease agreement/tenant income certification. Fiscal Year 2024 Monthly Income eligibility requirements are: For more information, contact Community Action of Etowah County at 256-546-9271. This article originally appeared on The Gadsden Times: Community Action of Etowah County offers heating assistance | ||||||||
OCN exam | OCN answers | OCN basics | OCN education | OCN learner | OCN learner | OCN test | OCN study help | OCN learn | OCN test plan | | ||||||||
Killexams test Simulator Killexams Questions and Answers Killexams Exams List Search Exams |
Customer Reviews help to evaluate the exam performance in real test. Here all the reviews, reputation, success stories and ripoff reports provided.
We hereby announce with the collaboration of world's leader in Certification Exam Dumps and Real Exam Questions with Practice Tests that, we offer Real Exam Questions of thousands of Certification Exams Free PDF with up to date VCE exam simulator Software.